Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02811263 · ClinicalTrials.gov registry record · Phase 3
High-dose Erythropoietin for Asphyxia and Encephalopathy
A Phase 3 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT02811263 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 500 participants.
The verdict
NCT02811263, a Phase 3 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
Hypoxic-ischemic encephalopathy (HIE) occurs when a baby gets reduced blood flow and oxygen to the brain near the time of birth. This results in death or neurologic disabilities including cerebral palsy and cognitive impairment in up to half of affected infants. This clinical trial will determine if the drug erythropoietin (Epo) added to hypothermia (usual therapy) will improve outcomes for infants suffering from HIE.
Interventions
- DRUG Normal saline placebo
- DRUG Erythropoietin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2017-01 |
| Est. Completion | 2022-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02811263
The ClinicalTrials.gov registry entry for NCT02811263 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline placebo is the first listed.
NCT02811263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02811263 about?
NCT02811263 is a clinical study titled "High-dose Erythropoietin for Asphyxia and Encephalopathy". Hypoxic-ischemic encephalopathy (HIE) occurs when a baby gets reduced blood flow and oxygen to the brain near the time of birth. This results in death or neurologic disabilities including cerebral palsy and cognitive impairment in up to half of affected infants. This clinical trial will determine if...
What is the current status of trial NCT02811263?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2017-01. Estimated completion is 2022-04.
What interventions are being tested in trial NCT02811263?
The interventions under investigation include: Normal saline placebo (DRUG), Erythropoietin (DRUG).
Who is sponsoring clinical trial NCT02811263?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.